BioCardia

OverviewSuggest Edit

BioCardia is a regenerative medicine company developing therapeutics for cardiovascular diseases with unmet medical needs. It offers biotherapeutic solutions for cardiovascular disease in its CardiAMP and CardiALLO therapies.

TypePrivate
Founded2002
HQSan Carlos, CA, US
Websitebiocardia.com

Latest Updates

Employees (est.) (Dec 2018)27(+13%)
Revenue (FY, 2019)$710 K(+14%)
Share Price (Jan 2021)$3.8 (+4%)
Cybersecurity ratingAMore

Key People/Management at BioCardia

Peter Altman

Peter Altman

President & CEO
Eric Duckers

Eric Duckers

CMO
David McClung

David McClung

CFO
Debby Holmes-Higgin

Debby Holmes-Higgin

VP, Clinical & Study Recruiting
Phil Pesta

Phil Pesta

VP of Operations
Show more

BioCardia Office Locations

BioCardia has an office in San Carlos
San Carlos, CA, US (HQ)
125 Shoreway Rd Suite B
Show all (1)

BioCardia Financials and Metrics

Summary Metrics

Founding Date

2002

BioCardia latest funding size

$7.40 m
Show all financial metrics

BioCardia Revenue

Embed Graph
View revenue for all periods
BioCardia's revenue was reported to be $710 k in FY, 2019
USD

Revenue (Q2, 2020)

27.0k

Net income (Q2, 2020)

(3.6m)

EBIT (Q2, 2020)

(3.6m)

Cash (30-Jun-2020)

11.1m
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

479.0k625.0k710.0k

Revenue growth, %

30%

Cost of goods sold

690.0k517.0k358.0k

Gross profit

(211.0k)108.0k352.0k
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

137.0k112.0k130.0k199.0k239.0k84.0k216.0k86.0k194.0k38.0k27.0k

Cost of goods sold

175.0k203.0k147.0k157.0k135.0k109.0k106.0k191.0k24.0k4.0k

Gross profit

(38.0k)(91.0k)(17.0k)42.0k104.0k(25.0k)110.0k(105.0k)170.0k34.0k

Gross profit Margin, %

(28%)(81%)(13%)21%44%(30%)51%(122%)88%89%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

12.7m5.4m5.6m

Accounts Receivable

95.0k274.0k147.0k

Prepaid Expenses

340.0k445.0k

Inventories

191.0k141.0k4.0k
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

19.0m15.1m13.3m9.7m6.8m4.8m2.8m517.0k8.9m2.6m11.1m

Accounts Receivable

121.0k142.0k90.0k127.0k191.0k170.0k287.0k204.0k103.0k179.0k214.0k

Prepaid Expenses

252.0k282.0k188.0k277.0k282.0k224.0k

Inventories

144.0k193.0k240.0k148.0k136.0k134.0k118.0k5.0k45.0k
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(12.3m)(14.0m)(14.7m)

Depreciation and Amortization

78.0k88.0k111.0k

Inventories

(56.0k)49.0k136.0k

Accounts Payable

377.0k119.0k171.0k
USDQ1, 2017

Financial Leverage

1.1 x
Show all financial metrics

BioCardia Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

BioCardia Online and Social Media Presence

Embed Graph

BioCardia News and Updates

BioCardia Issued New U.S. Patent for Technology that Enhances Control for Cardiac Therapies

Technology Anticipated to Impact Cardiac Biologic Therapies, Cardiac Arrhythmia, and Structural Heart Procedures Technology Anticipated to Impact Cardiac Biologic Therapies, Cardiac Arrhythmia, and Structural Heart Procedures

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Heart Failure Study as Designed

SAN CARLOS, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for …

Thinking about buying stock in Anavex Life Sciences, Veru Inc, vTv Therapeutics, BioCardia, or 22nd Century Group?

NEW YORK, Dec. 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVXL, VERU, VTVT, BCDA, and XXII. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

BioCardia, Inc. Announces $8.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for the purchase and sale of 1,888,889 shares of its common stock at a purchase price of $4.75 per share in a r…

BioCardia Reports Published Study Showing Helix Biotherapeutic Delivery System Used in CardiAMP Phase III Heart Failure Trial Has Fewest Adverse Events Among Competitive Delivery Systems

SAN CARLOS, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] today announced that the Company’s proprietary Helix Biotherapeutic Delivery System (the Helix System) demonstrated the best safety profile among clinical transendocardial catheter injection systems used for card…

BioCardia Reports Third Quarter 2020 Financial Results and Business Highlights

SAN CARLOS, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a leader in the development of autologous and allogenic cell therapies, today reported financial results and business highlights for the third quarter of 2020 and filed its quarterly report on Form 10-Q for the …
Show more

BioCardia Frequently Asked Questions

  • When was BioCardia founded?

    BioCardia was founded in 2002.

  • Who are BioCardia key executives?

    BioCardia's key executives are Peter Altman, Eric Duckers and David McClung.

  • How many employees does BioCardia have?

    BioCardia has 27 employees.

  • What is BioCardia revenue?

    Latest BioCardia annual revenue is $710 k.

  • What is BioCardia revenue per employee?

    Latest BioCardia revenue per employee is $26.3 k.

  • Who are BioCardia competitors?

    Competitors of BioCardia include FIRE1, ReShape Lifesciences and HDL Therapeutics.

  • Where is BioCardia headquarters?

    BioCardia headquarters is located at 125 Shoreway Rd Suite B, San Carlos.

  • Where are BioCardia offices?

    BioCardia has an office in San Carlos.

  • How many offices does BioCardia have?

    BioCardia has 1 office.